John completed his PhD in Microbiology at the University of Otago, New Zealand, identifying and characterising antimicrobial peptides (AMPs) produced by Streptococci. He then completed post-doctoral research positions studying the different mechanism of action these AMPs have and potential mechanisms of resistance to them. John joined BLIS Technologies in 2011, where he oversees the R&D, Clinical, Regulatory and IP strategies. John also holds an adjunct position with the University of Otago.